Harmony Biosciences Holdings, Inc. (HRMY) Stock Analysis

Harmony Biosciences Holdings, Inc. (HRMY) Stock Analysis — AI Research | MarketCI

HRMY

Market Closed

Harmony Biosciences Holdings, Inc.

NASDAQHealthcare Biotechnology

293 employees

CEO: Jeffrey Dayno

Founded: 2020

$35.32

+$0.00(+NaN%)

Market Cap

2.04B

Beta

0.94

52W Range

N/A

Dividend Yield

0.00%

Overview Forecasts Fundamental Market Sentiment Valuation Ownership

HRMY Price Chart

Historical price performance

Loading MCI price data...

MarketCI Investment Signals

AI-synthesized investment signal for HRMY built from valuation, fundamentals, sentiment, and risk models

Investment Signal

Buy

Pass %

71.43%

Score

5/7

Fair Value Estimate

Cash flow analysis • Multiple methods

$114.50

AI Price Target

Machine learning • Price prediction

$33.89

Market Sentiment

News & social media analysis

0.00

Value Investor Price

Classic value analysis

$14.11

Financial Health

Bankruptcy risk assessment

5.40

Quality Score

Financial strength rating

5.00

AI Investment Grade

Deep analysis of filings & news

75.00

Key Investment Highlights

Important factors affecting HRMY investment thesis

Due Diligence Analysis

Investment criteria assessment and scoring

Overall Assessment

70.73% Good

Conditions Met

29.00/41.00

Due Diligence Score

70.73%

Due Diligence Conditions

Investment analysis conditions and results


	Fail
	Pass
	Fail
	Pass
	Fail
	Pass

Showing 1 to 6 of 46 conditions